Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
15 Leser
Artikel bewerten:
(0)

12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

DUBLIN, Aug. 28, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9w6lh9/12th_annual) has announced the addition of the "12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production" report to their offering.

The 2015 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production. The report contains the industry's definitive, quantitative analysis and includes 12 years of biopharma trends as well as a review of current opportunities and in-depth coverage by several subject matter experts of critical issues affecting the industry.

The survey includes responses from 237 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations from 28 countries. The methodology also includes responses from an additional 164 direct suppliers of raw materials, services and equipment to this industry.

Top trends identified include:

- Focus today is on manufacturing and productivity
- Operations budgets are growing, from R&D to new capital equipment
- Single-use systems and disposable devices among the new bio-innovations most in demand
- U.S. and EU are stepping up their Biosimilars pipeline
- Hiring growing rapidly in key areas; 51% of companies unable to hire the right PD staff
- China is now the #1 "potential" outsourcing destination
- Suppliers are increasing their R&D and focus on improved productivity
- Fill-Finish operations are going high-tech and single-use


- Bioprocessing is getting better as failure rates have been almost cut in half over the past 8 years

Key Topics Covered:

Chapter 1: Introduction and Discussion

Chapter 3: Emerging Issues in Biopharmaceutical Manufacturing

Chapter 4: Capacity Utilization

Chapter 5: Current and Future Capacity Constraints

Chapter 6: Future Capacity Expansions

Chapter 7: Outsourcing Trends in Biopharmaceutical Manufacturing

Chapter 8: Disposables and Single-Use Systems in Biopharmaceutical Manufacturing

Chapter 9: Downstream Purification

Chapter 10: Quality Issues, Batch Failures, and PAT in Biopharmaceutical Manufacturing

Chapter 11: Hiring, Employment Growth, and Training in Biopharmaceutical

Chapter 12: Fill and Finish

Chapter 13: Suppliers to Biopharmaceutical Manufacturing and Life Sciences

For more information visit http://www.researchandmarkets.com/research/9w6lh9/12th_annual

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.